Three Innovative Ideas Receive $10,000 Prizes in Patients | Choices | Empowerment Competition

AmgenThe Amgen Foundation and Ashoka's Changemakers today announced three winners for the Patients | Choices | Empowerment competition. Each winner will receive a $10,000 cash prize and was selected by the public for their innovative solutions that empower and elevate patients' voices to improve health outcomes.

Out of 10 finalists, the entries receiving the most votes in the Changemakers.com competition are:

1. CureTogether - Crowdsourced Patient Experience
2. Educating Tuberculosis patients for excellent results
3. SMS Now! A Life Depends on It.

In addition, selected entries may be considered for additional grants totaling up to $1 million from the Amgen Foundation.

"The Patients | Choices | Empowerment winners demonstrate that it is possible to create innovative tools and resources that empower patients and offer collaborative solutions at every stage of healthcare," said Jean Lim, president of the Amgen Foundation. "This competition has helped to build a global community of innovators who are working to ensure that patients have an active role in their personal healthcare. We look forward to reviewing the entries to identify sustainable solutions that both the Amgen Foundation and other interested funders can support."

The winning entries are crowdsourcing quantitative data to help patients make more informed choices about their healthcare; removing the stigma around tuberculosis and encouraging and supporting treatment; and utilizing the internet and mobile technology to connect volunteer blood donors with patients. All of these innovations demonstrate global solutions.

"The Patients | Choices | Empowermentcompetition uncovered ideas that help patients makedecisions with confidence and clarity,in concertwithpeople who careand can help," said Diana Wells, president of Ashoka. "We are so pleased with the online community that joined the Changemakers platform, voted, and shared their feedback on these innovative solutions. We are also incredibly thankful to our expert judges and commentators who contributed to the creation of a rich, global dialogue on the important issues that ultimately resulted in the selection of three outstanding entries."

In addition to the $10,000 cash prizes, the three Patients | Choices | Empowermentcompetition winners will be featured on Changemakers.com as innovative ideas for empowering the patient and providing avenues for informed decisions.

About Ashoka's Changemakers
Ashoka's Changemakers is a community of action that connects social entrepreneurs around the globe to share ideas, inspire, and mentor each other. Through its online collaborative competitions and open-source process, Changemakers.com is one of the world's most robust spaces for launching, discussing, and funding ideas to solve the world's most pressing social problems. Changemakers builds on Ashoka's three decade history and belief that we all have the ability to be a Changemaker. www.Changemakers.com

About the Amgen Foundation
The Amgen Foundation seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live and work. Since 1991, the Foundation has made more than $140 million in grants to nonprofit organizations throughout the United States, Puerto Rico, and Europe that impact society in inspiring and innovative ways, and those that provide disaster relief efforts both domestically and internationally.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

Boehringer Ingelheim and OSE Immunotherapeutics an…

Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...